Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CHSY3 antisense RNA 1 (CHSY3-AS1) is a putative long non-coding RNA thought to be transcribed in the antisense direction relative to the CHSY3 gene. Antisense RNAs generally function by regulating the expression of their sense gene through transcriptional or post-transcriptional mechanisms, including affecting mRNA stability, translation, and chromatin structure. However, CHSY3-AS1 is not described in scientific literature or major molecular databases, is not recognized as a therapeutic target, and there are no data about its biological function, disease associations, or involvement in drug interactions. Its annotation may be speculative, incomplete, or incorrect, and care should be taken not to confuse it with the CHSY3 protein-coding gene, which is a validated enzyme involved in chondroitin sulfate synthesis and cancer biology. For structured datasets, CHSY3-AS1 should be flagged as potentially incorrect or lacking supporting evidence as a valid molecular target.
Not defined; general antisense RNAs can regulate their sense gene via transcript stability, translation repression, or epigenetic effects, but this has not been shown for CHSY3-AS1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CHSY3 antisense RNA 1 (CHSY3-AS1).